Sanofi 'lacks megadeal motivation' alongside lackluster Q1
This article was originally published in Scrip
Sanofi does not have the same incentive to conduct megadeals as some other big pharma companies, according to CEO Christopher Viehbacher. "We already have a much greater degree of diversification than some of our peers, and we are number one, two or three in each of the markets that we're in, so there is not the same motivation for us to try to do swaps," said Mr Viehbacher, apparently ruling out any potential jumping on the megadeal bandwagon that is sweeping through the sector in the wake of the Novartis/GlaxoSmithKline/Eli Lilly mega asset swap of last week.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.